717results about "Fused cells" patented technology

Recombinant NK cells, and especially recombinant NK-92 cells express a chimeric antigen receptor (CAR) having an intracellular domain of FcεRIγ. Notably, CAR constructs with an intracellular domain of FcεRIγ had a substantially prolonged duration of expression and significantly extended cytotoxicity over time. The CAR may be expressed from RNA and DNA, preferably as a tricistronic construct that further encodes CD16 and a cytokine to confer autocrine growth support. Advantageously, such constructs also enable high levels of transfection and expression of the recombinant proteins and provide a convenient selection marker to facilitate rapid production of recombinant NK / NK-92 cells.

Provided is the use of a protein derived from wheat and a biomaterial related thereto in increasing the yield per plant and grain protein content of a crop. The protein is designated as SWEET11, and may be a protein having an amino acid sequence as shown in sequence 9, sequence 6 or sequence 3 in the sequence listing. The wheat SWEET11 protein (TaSWEET11) is over-expressed in the Zhengmai 7698 wheat variety (nationally approved), and it is found that the over-expression of TaSWEET11 can significantly improve the thousand-grain weight of wheat grains and increase the yield. In addition, the over-expression of TaSWEET11 also increases the protein content in the wheat grain, significantly improving the grain quality while increasing the yield. The TaSWEET11 protein can be used for breeding and quality improvement of crops.

The invention relates to the technical field of biological medicine, in particular to a monoclonal antibody of BRVA virus VP7 protein and an epitope and application of the monoclonal antibody. The invention provides a hybridoma cell strain (preservation number: CCTCC NO: C202570). A monoclonal antibody prepared from the hybridoma cell strain can be combined with VP7 protein of G6, G8 and G10 type BRVA; the antigen epitope amino acid sequence of the monoclonal antibody is SEQ ID NO: 1. The monoclonal antibody and the antigen epitope peptide provided by the invention have broad-spectrum neutralizing activity, and provide a new strategy and tool for prevention and control of BRVA.

The present invention provides an antibody binding to human CD73, a preparation method therefor, and a use thereof. The monoclonal antibody of the present invention can bind to a CD73 antigen with high specificity, has high affinity, has remarkable anti-tumor activity and the like, and has excellent clinical application prospects.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.

The invention provides a TM125 monoclonal antibody and a preparation method and application of a kit of the TM125 monoclonal antibody. The monoclonal antibody hybridoma cell strain TM125 is preserved in the China General Microbiological Culture Collection Center (CGMCC) with the preservation number of CGMCC No.46109, and the prepared monoclonal antibody can effectively recognize the TM125.

The present disclosure provides methods and compositions relating to inhibiting the activity of an epithelial modulatory protein in a cell, and reversing or preventing changes in a cell associated with a disease or condition, such as a fibrotic disease or condition, including the use of an inhibitor of epithelial modulatory protein activity. Provided herein are isolated antibodies, or antigen-binding fragments thereof, that specifically bind to epithelial regulatory proteins as exemplary inhibitors of epithelial regulatory protein activity. Also disclosed are methods and compositions useful for treating or preventing a fibrotic disease or condition in a subject, e.g., including an inhibitor of epithelial regulatory protein activity. The present disclosure also includes kits comprising compositions useful in performing the disclosed methods.

A monoclonal humanized antibody or antigen-binding fragment thereof that specifically bind to the TRBV9 family of the human T cell receptor. A nucleic acid encoding the antibody or antigen-binding fragment thereof, an expression vector, a method for preparing the antibody, and use of the antibody in treatment of diseases or disorders associated with the human T cell receptor family. The generation of antibodies that can be used for treating, in particular AS, celiac disease and malignant blood diseases, the pathogenesis of which involves the TRBV9 family TCRs.

The present disclosure is directed to human IgE antibodies and fragments thereof binding to galactose-α-1,3-galactose, a known red meat allergen, and methods for use thereof.

Described herein are embodiments relating to manipulation of populations and sex ratio in populations through DNA sequence modifications.

The invention discloses a hybridoma cell strain 2D2 as well as a monoclonal antibody and application thereof. The invention also discloses an application of the anti-Tilletia foetida monoclonal antibody in detection of Tilletia foetida teliospore. The invention also discloses an HRP (horse radish peroxidase) coupled Tilletia foetida monoclonal antibody. The invention also discloses a detection kit. The monoclonal antibody as well as the coupling antibody and the kit thereof have the characteristic of specifically recognizing Tilletia foetida, and have a wide application prospect in detection of Tilletia foetida wheat in the fields of wheat import and export trade and market circulation.

This disclosure provides a technology for adapting host cells to maximize production and improve quality of viral vectors and particles. Cell hybrids are formed from parental cell lines, and divided or cloned into multiple aliquots for testing. Aliquots are chosen that have high production capacity and phenotypic features for virus production, such as an optimal level of intracellular organelles, and used to establish producer cell lines. The producer cells can be genetically altered to express a transgene that encodes viral elements for production of the viral vectors or particles with a therapeutic payload. The hybrid producer cells generate more viral vectors or particles per cell with higher functional titer, thereby lowering the cost of production of pharmaceutical agents for use in gene therapy and immunization.

The present invention provides, in certain aspects, a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15), and methods for producing such cells. The invention further provides methods of using a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15) to treat cancer in a subject or to enhance expansion and / or survival of NK cells.

The present invention discloses a hybridoma cell line 2D2 and a monoclonal antibody and application thereof. The present invention also discloses the application of the anti-light stinking smut monoclonal antibody in the detection of light stinking smut winter spores. The present invention also discloses an HRP-coupled light stinking smut monoclonal antibody. The present invention also discloses a detection kit. The monoclonal antibody and the coupled antibody and the kit involved in the present invention have the characteristics of specifically recognizing light stinking smut, and have broad application prospects for detecting light stinking smut wheat in the fields of wheat import and export trade and market circulation.

The invention relates to the technical field of biology, and discloses an anti-human PVRIG antibody and application thereof. The anti-human PVRIG antibody disclosed by the invention is specifically combined with a human PVRIG antigen and can be used for tumor treatment.

Provided herein are antibodies and antibody fragments that bind to human TNFRSF25. The antibodies may be monoclonal and / or biparatopic antibodies and / or single- chain fragment variable (scFv) antibodies. Methods of treating or preventing diseases or disorders associated with inflammation and / or autoimmunity are provided, comprising administering to a patient in need thereof an effective amount of a human TNFRSF25- binding antibody.

The present invention relates to monoclonal humanized antibodies or antigen-binding fragments thereof that specifically bind to the TRBV9 family of human T-cell receptors. The present invention also relates to nucleic acids encoding said antibodies or antigen-binding fragments thereof, expression vectors, methods for preparing said antibodies and the use of said antibodies in the treatment of diseases or disorders associated with said family of human T-cell receptors. The present invention relates to the production of antibodies that can be used to treat, inter alia, ankylosing spondylitis (AS or Bechterev's disease), celiac disease and blood cancers, whose pathogenesis involves T-cell receptors of the TRBV9 family.

To provide anti-BAG2 antibodies and methods of treating cancer.SOLUTION: An antibody or antigen binding fragment thereof that specifically binds to a BAG2 polypeptide, and a method for treating cancer therewith.SELECTED DRAWING: Figure 1

The present invention relates to using monoterpene or sesquiterpene to permeabilize the blood brain barrier. The present invention relates to a method of treating a central nervous system (CNS) cancer wherein perillyl alcohol (POH) is administered to a mammal before or concurrently with a therapeutic agent that is a chimeric antigen receptor T-cell (CAR-T cell). The POH and CAR-T cells can be administered by intraarterial injection. The CNS cancer can be a malignant glioma, pilocytic astrocytomas (grade I), meningiomas, metastatic brain tumors, or pituitary adenomas.

The present specification provides a monoclonal antibody that specifically binds aggregated, non-phosphorylated α-synuclein and a hybridoma producing it. Also disclosed are methods of generating antibodies that specifically binds aggregated, non-phosphorylated α-synuclein and uses thereof. Uses of anti-α-synuclein antibody in detection and diagnostic assays, and for prophylaxis or therapy of α-synuclein-associated neurodegenerative diseases, are also disclosed.

The invention provides a method for identifying the immune state of a subject, and the use of an agent for detecting the level of IL-1R2 in a sample from the subject in the preparation of a product for identifying the immune state of the subject. The invention also provides an antibody binding to human IL-1R2 and a use thereof, and a hybridoma cell generating the antibody binding to human IL-1R2 and a use thereof.

This invention provides antibodies or functional antibody fragments or probes thereof targeting a unique set of antigens recognized in cancer. The invention comprises a nucleotide sequence derived from the L2A5 monoclonal antibody. The antibodies or functional antibody fragments or probes thereof include variable heavy chain domains and variable light chain domains having the amino acid sequences provided herein. The DNA / amino acid sequence binding is unique and has never been previously described. The invention further provides antibodies or functional antibody fragments or conjugates or recombinant proteins useful for the detection, treatment, and prevention of human diseases, including cancer.

The present invention relates to using monoterpene or sesquiterpene to permeabilize the blood brain barrier.

The present invention relates to a novel anti-CD40 antibody and use thereof and, more specifically, to a novel anti-CD40 antibody and use thereof, wherein the antibody comprises a complementarity determining region of a specific sequence and exhibits an excellent antagonistic effect by blocking CD40-CD40L signaling. The novel anti-CD40 antibody of the present invention exhibits an excellent antagonistic effect by blocking CD40-CD40L signaling, and thus can be widely used as a preparation for preventing or treating various diseases, such as autoimmune diseases and chronic inflammatory diseases, and as a preparation for inhibiting immune rejection at the time of transplantation.

Some embodiments of the methods and compositions disclosed herein relate to immune cells that have been engineered to express chimeric antigen receptors and / or genetically modified to increase one or more aspects of the effectiveness of the immune cells in cellular immunotherapy. Some embodiments relate to genetic modifications that reduce potential side effects of cellular immunotherapy. In some embodiments, a combination of cells is used to achieve rapid and long-term tumor reduction with reduced or eliminated potential for graft-versus-host effects.

The present invention relates to a method for producing a plant or isolated plant cells for producing collagen, a nucleic acid construct used therein, and a method for producing collagen using the plant or isolated plant cells.

The invention belongs to the technical field of biology, and particularly relates to a hybridoma cell strain capable of secreting a clostridium perfringens ETX monoclonal antibody with neutralizing activity and application of the hybridoma cell strain. On the basis of natural toxin, an indirect ELISA (enzyme-linked immunosorbent assay) detection method is established by utilizing a non-toxic ETX single amino acid site protein mutant, and a series of hybridoma cell strains secreting an anti-clostridium perfringens ETX monoclonal antibody are screened; the hybridoma cell strain can stably and efficiently secrete a monoclonal antibody with neutralizing activity and a monoclonal antibody without neutralizing resistance respectively, and large-scale batch production can be realized. According to the present invention, the clostridium perfringens ETX monoclonal antibody is firstly utilized to establish the ETX antigen ELISA detection method, and the method has characteristics of simple sample operation, low cost, rapid reaction, strong specificity and the like, can provide the reference for the diagnosis of clostridium perfringens, and provides the basis for the research of the related vaccine potency test substitution method.

Monoclonal antibody that specifically binds IL-1RAcP, or an antigen binding fragment thereof, comprising:a) a heavy chain variable region (VH) comprising CDR1H, CDR2H and / or CDR3H, wherein the CDR1H region comprises an amino acid sequence selected from the group of SEQ ID NO: 155-231,wherein the CDR2H region comprises an amino acid sequence selected from the group of SEQ ID NO: 232-308,and wherein the CDR3H region comprises an amino acid sequence selected from the group of SEQ ID NO: 309-385; andb) a light chain variable region (VL) comprising CDR1L, CDR2L and / or CDR3L, wherein the CDR1L region comprises an amino acid sequence selected from the group of SEQ ID NO: 386-462,wherein the CDRL2 region comprises an amino acid sequence selected from the group of SEQ ID NO: 463-539,and wherein the CDR3L region comprises an amino acid sequence selected from the group of SEQ ID NO: 540-616The monoclonal antibody is characterized in that it inhibits IL-1RAcP induced NFkB activity, useful in treatment of IL-1RAcP related diseases.

The invention discloses a monoclonal antibody which is specifically combined with a microtubule associated protein tau (microtubule associated protein with 217 Thrphorylation, pTau217) of which the 217 site is phosphorylated by threonine, and a preparation method of the monoclonal antibody. The invention provides an amino acid sequence of a variable domain of the monoclonal antibody, and an amino acid sequence of a complementary determining region (CDR) contained in the amino acid sequence of the variable domain of the monoclonal antibody. The monoclonal antibody disclosed by the invention has the capability of specifically recognizing and remarkably combining pTau217, and can be used for developing and producing pTau217 clinical in vitro diagnosis (IVD) medical equipment products based on an immunological detection principle as a reagent raw material.

The present invention provides an IL13RA2-targeting herpes simplex virus in which an anti-IL13RA2 antibody or an antigen-binding fragment thereof is presented on the viral surface. Also provided is an anti-IL13RA2 antibody or an antigen-binding fragment thereof capable of specifically recognizing tumor cells.